The Transcera team is excited to participate in the 8th annual Targeted Protein Degradation Summit next week, where we'll be sharing new data showcasing the power of our ceramide platform to eliminate a wide range of disease-driving proteins. As part of the 2nd Generation Protein Modulation Day on Thursday, October 30th, our CSO, Justin Wolfe, will detail Transcera's unique approach in an oral presentation, and our CEO, Hunter Goble, will join a panel discussion on the future of protein degraders. If you'll be in attendance, drop us a line - we'd love to connect! 📍 Targeted Protein Degradation Summit | Boston, MA 🗓️ Thursday, October 30 🔮 9:15am Panel Discussion: Exploring the Frontier Beyond Traditional Degradation: Challenges, Opportunities & Emerging Modalities 🧑🔬 1:00pm Harnessing Sphingolipid Biology for Targeted Degradation of Extracellular Proteins
Transcera
Biotechnology
Cambridge, Massachusetts 759 followers
Harnessing sphingolipid biology to create transformative medicines for people living with chronic disease.
About us
Transcera is a biotech company transforming treatment of chronic disease through a new approach to biologic medicines.
- Website
-
http://www.transcera.com
External link for Transcera
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
700 Main St
Cambridge, Massachusetts 02139, US
-
Get directions
127 Western Avenue
Allston, Massachusetts 02134, US
Employees at Transcera
Updates
-
We've moved! Transcera is now headquartered at Portal Boston, in the beautiful new Southline facility (in the former Boston Globe Media building!). We're excited to continue advancing sphingolipid-based therapeutics from our new home in Boston. Thanks to the Portal Innovations team for the warm welcome. We also want to thank LabCentral - Transcera's first home - for providing an incredible space and community for biotech incubation. We loved our time on Main Street and will always value the friendships made and milestones achieved there. See you around.
Please take a moment to welcome Transcera to Portal Boston at Southline! Transcera is pioneering targeted extracellular protein degradation using novel sphingolipid biology discovered at Harvard. Unlike receptor-mediated protein degraders, Transcera’s degraders work across diverse tissues, have extended half-life for durable target depletion, and are simple to manufacture. With a rapidly advancing pipeline of degraders for immune disorders, Transcera aims to transform the treatment landscape for chronic diseases driven by extracellular proteins. The company is backed by Digitalis Ventures, Pear VC, KdT Ventures, and Xora Innovation. Welcome to Portal - we're excited to have the Transcera team at Southline!
-